Page last updated: 2024-11-07

prednisone and Panuveitis

prednisone has been researched along with Panuveitis in 26 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Panuveitis: Inflammation in which both the anterior and posterior segments of the uvea are involved and a specific focus is not apparent. It is often severe and extensive and a serious threat to vision. Causes include systemic diseases such as tuberculosis, sarcoidosis, and syphilis, as well as malignancies. The intermediate segment of the eye is not involved.

Research Excerpts

ExcerptRelevanceReference
"To compare the benefits of fluocinolone acetonide implant therapy versus systemic corticosteroid therapy supplemented (when indicated) with immunosuppression for intermediate uveitis, posterior uveitis, and panuveitis."9.20Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up ( Altaweel, MM; Drye, LT; Holbrook, JT; Jabs, DA; Kempen, JH; Sugar, EA; Thorne, JE, 2015)
"These results suggest that fluocinolone acetonide implant therapy is associated with a clinically important increased risk of glaucoma and cataract with respect to systemic therapy, suggesting that careful monitoring and early intervention to prevent glaucoma is warranted with implant therapy."9.20Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatmen ( , 2015)
"To compare the relative effectiveness of systemic corticosteroids plus immunosuppression when indicated (systemic therapy) versus fluocinolone acetonide implant (implant therapy) for noninfectious intermediate, posterior, or panuveitis (uveitis)."9.15Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. ( Altaweel, MM; Holbrook, JT; Jabs, DA; Kempen, JH; Louis, TA; Sugar, EA; Thorne, JE, 2011)
"To compare the benefits of fluocinolone acetonide implant therapy versus systemic corticosteroid therapy supplemented (when indicated) with immunosuppression for intermediate uveitis, posterior uveitis, and panuveitis."5.20Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up ( Altaweel, MM; Drye, LT; Holbrook, JT; Jabs, DA; Kempen, JH; Sugar, EA; Thorne, JE, 2015)
"These results suggest that fluocinolone acetonide implant therapy is associated with a clinically important increased risk of glaucoma and cataract with respect to systemic therapy, suggesting that careful monitoring and early intervention to prevent glaucoma is warranted with implant therapy."5.20Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatmen ( , 2015)
"To compare the relative effectiveness of systemic corticosteroids plus immunosuppression when indicated (systemic therapy) versus fluocinolone acetonide implant (implant therapy) for noninfectious intermediate, posterior, or panuveitis (uveitis)."5.15Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. ( Altaweel, MM; Holbrook, JT; Jabs, DA; Kempen, JH; Louis, TA; Sugar, EA; Thorne, JE, 2011)
"Chronic use of corticosteroids for the treatment of uveitis has been linked with drug-associated toxicity and adverse events (AEs)."2.84Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials. ( Bao, Y; Betts, KA; Camez, A; Joshi, A; Mittal, M; Suhler, EB; Tari, S; Thorne, JE, 2017)
"Sarcoidosis is a potentially life-threatening, multisystem, granulomatous disease that can present with cutaneous manifestations in patients."2.46Ichthyosiform sarcoidosis: A case report and review of the literature. ( George, DE; Hsu, S; Kelley, BP; LeLeux, TM, 2010)
"This study causally examined the dose-response relationship between oral corticosteroids (OCS) exposure and long-term complications among noninfectious uveitis adult patients in the United States."1.51Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis. ( Chirikov, VV; Kwon, Y; Patel, D; Shah, R, 2019)
"Prednisone was tapered after 1 month."1.40Success with single-agent immunosuppression for multifocal choroidopathies. ( Godbold, J; Goldberg, NR; Jabs, DA; Lyu, T; Moshier, E, 2014)
"Optic neuropathy is an uncommon complication of MFCPU that may result in substantial visual morbidity."1.34Optic neuropathy complicating multifocal choroiditis and panuveitis. ( Dunn, JP; Jabs, DA; Kedhar, SR; Thorne, JE; Wittenberg, S, 2007)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (11.54)18.2507
2000's4 (15.38)29.6817
2010's18 (69.23)24.3611
2020's1 (3.85)2.80

Authors

AuthorsStudies
Takhar, JS1
Gonzales, JA1
Suhler, EB2
Thorne, JE4
Mittal, M1
Betts, KA1
Tari, S1
Camez, A1
Bao, Y1
Joshi, A1
Boiché, M1
Conart, JB1
Angioi-Duprez, K1
Medina, CA1
Fajardo, A1
Calderon, A1
Aracena, M1
Chirikov, VV1
Shah, R1
Kwon, Y1
Patel, D1
Faez, S1
Lobo, AM1
Unizony, SH1
Stone, JH1
Papaliodis, GN1
Sobrin, L2
Goldberg, NR1
Lyu, T1
Moshier, E1
Godbold, J1
Jabs, DA4
Caso, F1
Rigante, D1
Vitale, A1
Costa, L1
Bascherini, V1
Latronico, E1
Franceschini, R1
Cantarini, L1
Kempen, JH2
Altaweel, MM2
Drye, LT1
Holbrook, JT2
Sugar, EA2
Patel, A1
Modjtahedi, BS1
Freitag, SK1
Kazlas, MA1
Shantha, JG1
Crozier, I1
Varkey, JB1
Kraft, CS1
Lyon, GM1
Mehta, AK1
Carlson, RD1
Hill, CE1
Kumar, G1
Debiec, MR1
Patel, PS1
Olsen, TW1
Nussenblatt, RB1
Martin, DF1
Ströher, U1
Uyeki, TM1
Ribner, BS1
Smith, JR1
Yeh, S1
Kelley, BP1
George, DE1
LeLeux, TM1
Hsu, S1
Payne, JF1
Srivastava, SK1
Wells, JR1
Grossniklaus, HE1
Bouomrani, S1
Farah, A1
Ayadi, N1
Béji, M1
Louis, TA1
Matsumiya, W1
Kusuhara, S1
Yamada, Y1
Azumi, A1
Negi, A1
Butler, NJ1
Adán, A1
Llorenç, V1
Mesquida, M1
Pelegrín, L1
de Popa, DP1
Smochină, S1
Khurana, RN1
Albini, T1
Dea, MK1
Rao, NA2
Lim, JI1
Wittenberg, S1
Kedhar, SR1
Dunn, JP1
Ahmed, M1
Niffenegger, JH1
Jakobiec, FA1
Ben-Arie-Weintrob, Y1
Gion, N1
Androudi, S1
Folberg, R1
Raizman, MB1
Margo, CE1
Smith, ME1
McLean, IW1
Caya, JG1
Foster, CS1
Bielory, L1
Sohn, T1
Rescigno, R1
Tsai, JC1
Forster, DJ1
Ober, RR1
Burgoyne, CF1
Verstraeten, TC1
Friberg, TR1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Multicenter Uveitis Steroid Treatment (MUST) Trial[NCT00132691]Phase 4255 participants (Actual)Interventional2005-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cataract - Incident Cataract

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Fluocinolone Acetonide Implant90.7
Systemic Therapy44.9

Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis

Best-corrected visual acuity was measured as the number of letters read from standard logarithmic visual acuity charts by study-certified examiners who were masked to treatment. Visual acuity was measured at all study visits. The primary outcome was eye-specific change in visual acuity from baseline to 2-year follow-up. Positive change values indicate improved vision while negative change values indicate vision has gotten worse. A change of 7.5 letters is considered clinically meaningful. (NCT00132691)
Timeframe: 24 months

Interventionletters (Mean)
Flucinolone Acetonide Implant6.0
Systemic Therapy3.2

Change in Self-reported Vision-related Function as Measured by the National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ 25) Vision Targeted Composite Score From Baseline to 24 Months

The NEI-VFQ 25 measures the effect of visual disability/symptoms with generic health and task-oriented domains. The range for the composite score is 0 to 100; higher scores are associated with better visual function. A change of 4 to 6 points is considered to be a clinically meaningful difference. (NCT00132691)
Timeframe: 24 months

Interventionunits on a scale (composite score) (Mean)
Fluocinolone Acetonide Implant11.44
Systemic Therapy6.80

Change in SF-36 Mental Component Score From Baseline to 24 Months

Self-reported health related QoL was measured with the SF 36 survey. The mental component score for the SF 36 is a summary measure of mental health primarily based on the social functioning, role emotional, mental health and vitality domains. The score is scaled to a population norm with a mean of 50 and standard deviation of 10. Higher scores represent better outcomes. The mean change in scores between baseline and 24 months was calculated for each treatment group. (NCT00132691)
Timeframe: 24 months

Interventionunits on a scale (Mean)
Flucinolone Acetonide Implant2.55
Systemic Therapy-1.1

Change in SF-36 Physical Component Score From Baseline to 24 Months

Self-reported health related QoL was measured with the SF 36 survey. The physical component score for the SF 36 is a summary measure of physical health primarily based on the physical functioning, role physical, bodily pain and general health domains of the survey. The score is scaled to a population norm with a mean of 50 and standard deviation of 10. Higher scores represent better outcomes. The mean change in scores between baseline and 24 months was calculated for each treatment group. A 3 to 5 point difference is considered to be clinically meaningful. (NCT00132691)
Timeframe: 24 months

Interventionunits on a scale (Mean)
Flucinolone Acetonide Implant1.15
Systemic Therapy-1.8

Diabetes Mellitus

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Flucinolone Acetonide Implant1.0
Systemic Therapy3.6

Glaucoma - Incident

Glaucoma was diagnosed by a glaucoma specialist through review of visual fields, clinical data, and fundus images. (NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Fluocinolone Acetonide Implant16.5
Systemic Therapy4.0

Hyperlipidemia - Incident

LDL greater than or equal to 160 mg/mL (NCT00132691)
Timeframe: 24 months

Interventionpercentage of participants at risk (Number)
Flucinolone Acetonide Implant9.8
Systemic Therapy11.0

Hypertension Diagnosis Requiring Treatment

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Flucinolone Acetonide Implant4.6
Systemic Therapy10.5

Intraocular Pressure - Incident IOP Elevation >= 10 mmHg Above Baseline

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Fluocinolone Acetonide Implant51.8
Systemic Therapy15.5

Intraocular Pressure - Incident IOP Greater Than or Equal to 24 mm Hg

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant53.1
Systemic Therapy18.7

Intraocular Pressure - Incident IOP Greater Than or Equal to 30 mm Hg

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant32.8
Systemic Therapy6.3

Intraocular Pressure - IOP-lowering Surgery

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant26.2
Systemic Therapy3.7

Intraocular Pressure (IOP) - Incident Use of IOP-lowering Medical Therapy (Percentage of Eyes With Uveitis That Were Not Being Treated With IOP-lowering Medical Therapy at Baseline and Underwent IOP Lowering Therapy During the 24 Month Follow-up.

The percentage of subjects who used topical or systemic treatment for elevated IOP at any time during the 2 year follow-up and were not on IOP-lowering therapy at baseline is reported. (NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant61.1
Systemic Therapy20.1

Macular Edema

center point macular thickness >= 240 micrometers assessed on OCT (Stratus OCT-3 [Carl Zeiss Meditec, Dublin, CA]) as graded by Central Reading Center (NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis (Number)
Flucinolone Acetonide Implant22
Systemic Therapy30

Mortality

(NCT00132691)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Flucinolone Acetonide Implant1.6
Systemic Therapy0

Uveitis Activity

Uveitis activity was determined by clinician assessment at each study visit. The study ophthalmologist evaluated each eye as active, inactive/never had uveitis or cannot assess. (NCT00132691)
Timeframe: 24 months

Interventionpercentage of eyes with uveitis (Number)
Fluocinolone Acetonide Implant12
Systemic Therapy29

Reviews

2 reviews available for prednisone and Panuveitis

ArticleYear
Ocular inflammatory disease in patients with polymyalgia rheumatica: A case series and review of the literature.
    Clinical rheumatology, 2016, Volume: 35, Issue:1

    Topics: Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Panuveitis; Polymyalgia Rheumatica; Pred

2016
Ichthyosiform sarcoidosis: A case report and review of the literature.
    Dermatology online journal, 2010, Aug-15, Volume: 16, Issue:8

    Topics: Antibodies, Antinuclear; Biopsy; Dermatologic Agents; Female; Granuloma; Humans; Hypercalcemia; Icht

2010

Trials

4 trials available for prednisone and Panuveitis

ArticleYear
Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
    Ophthalmology, 2017, Volume: 124, Issue:12

    Topics: Adalimumab; Administration, Oral; Adult; Anti-Inflammatory Agents; Double-Blind Method; Drug Combina

2017
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up
    Ophthalmology, 2015, Volume: 122, Issue:10

    Topics: Adult; Aged; Anti-Inflammatory Agents; Drug Implants; Female; Fluocinolone Acetonide; Follow-Up Stud

2015
Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatmen
    Ophthalmology, 2015, Volume: 122, Issue:10

    Topics: Adult; Aged; Anti-Inflammatory Agents; Cataract; Drug Implants; Female; Fluocinolone Acetonide; Foll

2015
Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
    Ophthalmology, 2011, Volume: 118, Issue:10

    Topics: Drug Implants; Drug Therapy, Combination; Female; Fluocinolone Acetonide; Glucocorticoids; Humans; I

2011

Other Studies

20 other studies available for prednisone and Panuveitis

ArticleYear
IgA Nephropathy-Associated Uveitis: A Case Presentation.
    Ocular immunology and inflammation, 2020, Oct-02, Volume: 28, Issue:7

    Topics: Administration, Oral; Adult; Female; Fluorescein Angiography; Glomerulonephritis, IGA; Glucocorticoi

2020
[Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
    Journal francais d'ophtalmologie, 2018, Volume: 41, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Huma

2018
Post-Streptococcal Uveitis: Case Report.
    Ocular immunology and inflammation, 2019, Volume: 27, Issue:7

    Topics: Administration, Oral; Dose-Response Relationship, Drug; Female; Fluorescein Angiography; Fundus Ocul

2019
Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis.
    Ophthalmic epidemiology, 2019, Volume: 26, Issue:1

    Topics: Administration, Oral; Data Analysis; Dose-Response Relationship, Drug; Drug-Related Side Effects and

2019
Success with single-agent immunosuppression for multifocal choroidopathies.
    American journal of ophthalmology, 2014, Volume: 158, Issue:6

    Topics: Adolescent; Adult; Aged; Azathioprine; Chorioretinitis; Choroiditis; Drug Therapy, Combination; Elec

2014
Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.
    Clinical rheumatology, 2015, Volume: 34, Issue:10

    Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal;

2015
Idiopathic Orbital Inflammation Presenting with Bilateral Panuveitis.
    Journal of pediatric ophthalmology and strabismus, 2016, Apr-23, Volume: 53 Online

    Topics: Adolescent; Fluorescein Angiography; Glucocorticoids; Humans; Magnetic Resonance Imaging; Male; Orbi

2016
Long-term Management of Panuveitis and Iris Heterochromia in an Ebola Survivor.
    Ophthalmology, 2016, Volume: 123, Issue:12

    Topics: Administration, Oral; Adult; Amides; Atropine; Drug Combinations; Ebolavirus; Eye Infections, Viral;

2016
Rosai-Dorfman disease simulating nodular scleritis and panuveitis.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2011, Volume: 129, Issue:4

    Topics: Diagnosis, Differential; Female; Histiocytes; Histiocytosis, Sinus; Humans; Immunoenzyme Techniques;

2011
[Bilateral chronic and granulomatous total uveitis following cutaneous leishmaniasis].
    Medecine et maladies infectieuses, 2011, Volume: 41, Issue:6

    Topics: Adolescent; Anti-Inflammatory Agents; Antiprotozoal Agents; Female; Granuloma; Humans; Leishmaniasis

2011
Sweet's syndrome with panuveitis resembling Behçet's disease.
    Japanese journal of ophthalmology, 2012, Volume: 56, Issue:3

    Topics: Behcet Syndrome; Betamethasone; Diagnosis, Differential; Fluorescein Angiography; Glucocorticoids; H

2012
Levofloxacin-associated panuveitis with chorioretinal lesions.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2012, Volume: 130, Issue:10

    Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Bites and Stings; Female;

2012
Tocilizumab treatment for recalcitrant uveitic macular edema.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2013, Volume: 251, Issue:9

    Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Female; Glucocor

2013
[Therapeutical difficulties in a patient with TB panuveitis and open angle glaucoma].
    Oftalmologia (Bucharest, Romania : 1990), 2002, Volume: 54, Issue:3

    Topics: Adult; Anti-Inflammatory Agents; Antihypertensive Agents; Antitubercular Agents; Drug Therapy, Combi

2002
Atypical presentation of multiple evanescent white dot syndrome involving granular lesions of varying size.
    American journal of ophthalmology, 2005, Volume: 139, Issue:5

    Topics: Adult; Choroid; Female; Fluorescein Angiography; Glucocorticoids; Humans; Optic Disk; Panuveitis; Pr

2005
Optic neuropathy complicating multifocal choroiditis and panuveitis.
    American journal of ophthalmology, 2007, Volume: 143, Issue:4

    Topics: Adult; Choroiditis; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged;

2007
Diagnosis of limited ophthalmic Wegener granulomatosis: distinctive pathologic features with ANCA test confirmation.
    International ophthalmology, 2008, Volume: 28, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Antineutrophil Cytoplasmic; Cyclophosphamide; Dacryocyst

2008
Bilateral red eyes in a patient infected with human immunodeficiency virus.
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 74, Issue:4

    Topics: AIDS-Related Opportunistic Infections; Diagnosis, Differential; Eye Infections, Bacterial; HIV Serop

1995
Panuveitis and multifocal retinitis in a patient with leucocytoclastic vasculitis.
    The British journal of ophthalmology, 1993, Volume: 77, Issue:5

    Topics: Adrenal Cortex Hormones; Delayed-Action Preparations; Female; Humans; Injections; Middle Aged; Panuv

1993
Tuberculin skin-test-induced uveitis in the absence of tuberculosis.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 1991, Volume: 229, Issue:3

    Topics: Adolescent; Female; Fluorescein Angiography; Fundus Oculi; Humans; Panuveitis; Prednisone; Retinal D

1991